Cas:436086-91-8 3-[(3,5-dimethylpyrazol-1-yl)methyl]-4-methoxybenzaldehyde manufacturer & supplier

Chemical Name:3-[(3,5-dimethylpyrazol-1-yl)methyl]-4-methoxybenzaldehyde

CAS.NO:436086-91-8

Synonyms:3-[(3,5-dimethylpyrazolyl)methyl]-4-methoxybenzaldehyde;3-[(3,5-dimethyl-1H-pyrazol-1-yl)methyl]-4-methoxybenzaldehyde;3-(3,5-Dimethyl-pyrazol-1-ylmethyl)-4-methoxy-benzaldehyde

Molecular Formula:C₁₄H₁₆N₂O₂

Molecular Weight:244.28900

HS Code:2933199090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:415.3ºC at 760mmHg

Density:1.12g/cm3

Index of Refraction:1.562

PSA:44.12000

Exact Mass:244.12100

LogP:2.36930

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3-[(3,5-dimethylpyrazolyl)methyl]-4-methoxybenzaldehyde chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-(3,5-Dimethyl-pyrazol-1-ylmethyl)-4-methoxy-benzaldehyde physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-[(3,5-dimethylpyrazolyl)methyl]-4-methoxybenzaldehyde Use and application,3-(3,5-Dimethyl-pyrazol-1-ylmethyl)-4-methoxy-benzaldehyde technical grade,usp/ep/jp grade.

Related News: Resonant exploits its proprietary IMPaCT tumor microenvironment models and data platform to discover novel, unappreciated targets and functionally active anti-tumor antibodies for difficult to treat tumors. 3-[(3,5-dimethylpyrazol-1-yl)methyl]-4-methoxybenzaldehyde manufacturer GlaxoSmithKline��s HIV drugs division ViiV Healthcare said on Saturday that the U.S. Food and Drug Administration declined to approve its long acting HIV injection. 3-[(3,5-dimethylpyrazol-1-yl)methyl]-4-methoxybenzaldehyde supplier When using the raw materials, as an API manufacturer we produce API in the large reactor in our plant. 3-[(3,5-dimethylpyrazol-1-yl)methyl]-4-methoxybenzaldehyde vendor Resonant exploits its proprietary IMPaCT tumor microenvironment models and data platform to discover novel, unappreciated targets and functionally active anti-tumor antibodies for difficult to treat tumors. 3-[(3,5-dimethylpyrazol-1-yl)methyl]-4-methoxybenzaldehyde factory The Darzalex-Rd regimen got its FDA go-ahead in transplant-ineligible patients in 2019 based on data from the same phase 3 MAIA trial showing it could pare down the risk of disease progression or death by 44% after a median follow-up of 28 months. Now, after 56.2 months of follow-up, over half of Darzalex patients were still alive without their disease worsening, a showing that’s again “unprecedented” for a front-line myeloma treatment, Tendler said.